

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934  
(Amendment No. )\*

CYTOKLONAL PHARMACEUTICS

---

(Name of Issuer)

Common Stock

---

(Title of Class of Securities)

23282G105

---

(CUSIP Number)

Paul F. Byrne c/o Janssen-Meyers Associates, L.P.  
17 State Street,  
NY, NY 10004 (212) 742-4200

---

(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and  
Communications)

11/2/95

---

\_\_\_\_\_(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed  
a statement on Schedule 13G to report the  
acquisition which is the subject of this  
Schedule 13D, and is filing this schedule because  
of Rule 13d-1(b)(3) or (4), check the following box \_\_\_\_.

Check the following box if a fee is  
being paid with the statement \_\_\_\_\_. (A fee is not required  
only if the reporting person: (1) has a  
previous statement on file reporting beneficial ownership  
of more than five percent of the class of  
securities described in Item 1; and (2) has filed no  
amendment subsequent thereto reporting beneficial  
ownership of five percent or less of such class.)  
(Sec Rule 13d-7.)

Note: Six copies of this statement, including  
all exhibits, should be filed with the  
Commission. See Rule 13d-1(a) for other parties  
to whom copies are to be sent.

\*The remainder of this cover page  
shall be filled out for a reporting person's  
initial filing on this  
form with respect to the subject class of  
securities, and for any subsequent amendment  
containing information which would alter  
disclosures provided in a prior cover page.

The information required on the remainder of this  
cover page shall not be deemed to be  
filed" for the purpose of Section 18 of the  
Securities Exchange Act of 1934 ("Act") or  
otherwise subject to the liabilities of that  
section of the Act but shall be subject to all  
other provisions of the Act (however, see the Notes).

1. Name of Reporting Person

Peter Janssen

---

S.S. or I.R.S. Identification No. of Above Person

---

2. Check the Appropriate Box if a Member of a Group  
(See Instructions before filling out)

a. \_\_\_\_\_ b. ☒ X

3. SEC USE ONLY

---

4. Source of Funds (See instructions before filling out).

AF

---

5. Check Box if Disclosure of Legal Proceedings is  
Required Pursuant to Items  
2(d) or 2(e).

---

6. Citizenship or Place of Organization

USA

---

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  
PERSON (Questions 7 - 10)

7. Sole Voting Power

---

8. Shared Voting Power

840,000 Common Stock

---

9. Sole Dispositive Power

---

10. Shared Dispositive Power

840,000 shares Common Stock

---

11. Aggregate Amount Beneficially Owned  
by Each Reporting Person

840,000 shares Common Stock

---

12. Check Box if the Aggregate Amount in Row  
(11) Excludes Certain Shares  
(See instructions before filling out)

NA

---

13. Percent of Class Represented by Amount in Row (11)

10.8%

---

14. Type of Reporting Person (See instructions before filling out)

IN

---